The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II study of neoadjuvant carboplatin, eribulin mesylate, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer.
Lee Steven Schwartzberg
Consultant or Advisory Role - Eisai
Honoraria - Eisai
Research Funding - Eisai
Kurt W. Tauer
No relevant relationships to disclose
Robert C. Hermann
Consultant or Advisory Role - Genentech/Roche
Honoraria - Genentech/Roche
Research Funding - Eisai; Genentech/Roche
Petros G. Nikolinakos
No relevant relationships to disclose
Arthur C. Houts
No relevant relationships to disclose